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BACKGROUND. The most important factor in predicting survival among women
with newly diagnosed breast cancer is the status of the axillary lymph nodes.
Although straightforward to define, the impact of micrometastases on survival
remains to be completely determined.
METHODS. A review of data from the Surveillance, Epidemiology, and End Results
Program of the National Cancer Institute was performed using 43,921 cases diag-
nosed from January 1988 through December 2001. Among women with invasive
breast carcinomas 2 cm undergoing a resection of the primary malignancy and
an axillary lymph node dissection, there were 42,197 cases without lymph node
metastases and 1724 cases with micrometastases. Survival differences among
these 2 groups were evaluated and are reported here.
RESULTS. Survival at 12 years was modestly affected by the presence of either sol-
itary (5.0%) or multiple lymph nodes (3.6%) with micrometastases when com-
pared with lymph node-negative cases. In subgroup analyses, the decreased
survival associated with micrometastases was inconsistent. The most significant
survival disadvantage associated with micrometastases was found in cases with
Grade 3 carcinomas.
CONCLUSIONS. The modest and variable impact of micrometastases on long-term
survival indicates that micrometastases are an important, but not a dominant,
prognostic indicator. Cancer 2006;107:1234–9.  2006 American Cancer Society.
KEYWORDS: breast cancer, micrometastases, SEER, multivariate analysis.
T he most significant prognostic indicator among women withnewly diagnosed breast cancer remains the status of the axillary
lymph nodes. There is substantial heterogeneity in women with
lymph node metastases, which is reflected in the pathologic sub-
classification of lymph nodes. The most subtle histologic subclass of
lymph node metastases, micrometastases, has been defined as
lymph nodes containing metastatic foci measuring no greater than
2 mm in diameter. This definition was first utilized by Huvos et al.1
in 1971 and was utilized in the AJCC TNM staging system from 1984
through 2002.2–5 In the most recent AJCC staging system, the defini-
tion of micrometastases has been further stratified to reflect the
increased detection of micrometastases through use of immunohis-
tochemical staining, reverse-transcriptase polymerase chain reaction
(RT-PCR), and the uncertain clinical significance of isolated tumor
cells identified as foci <0.2 mm.6
Although straightforward to define, the impact of lymph node
micrometastases on survival remains an unresolved issue.7–10 In ini-
tial series, women with micrometastases did not experience a survival
disadvantage when compared with women with lymph node-negative
Supported in part by National Institutes of Health
(NIH) grant N01-PC-35145.
Address for reprints: Douglas Maibenco, MD,
PhD, Surgical Specialists of Decatur, 1750 E.
Lake Shore Dr., Suite 200, Decatur, IL 62521;
Fax: (217) 428-6322; E-mail: maibencod@
insightbb.com
Received March 22, 2006; revision received May
16, 2006; accepted May 30, 2006.
ª 2006 American Cancer Society
DOI 10.1002/cncr.22112
Published online 9 August 2006 in Wiley InterScience (www.interscience.wiley.com).
1234
breast cancer,1,11,12 suggesting that micrometastases
are not of major clinical interest.
It was subsequently recognized that these initial
series were frequently limited in size and length of
follow-up, and might not detect small differences in
survival. The impact of study size and follow-up time
was first appreciated by Rosen et al.13 After 6 years
of follow-up, Rosen14 noted that cases with microme-
tastases had a survival rate that was no different than
lymph node-negative cases. After 12 years of follow-
up, however, the survival rates of cases with micro-
or macrometastases were nearly identical, and signif-
icantly worse than that for lymph node-negative
cases. In subsequent studies with more cases and
longer follow-up, women with micrometastatic breast
cancer experience a survival disadvantage in all but 1
series.15–22
The present study was performed to determine if
micrometastases may be a significant prognostic in-
dicator apart from other risk factors. Cases with
micrometastases were stratified by the number of
involved lymph nodes to determine if solitary lymph
node metastases are associated with a survival disad-
vantage comparable to multiple lymph nodes with
micrometastases.
MATERIALS AND METHODS
Cases were identified from data collected by 11
population-based cancer registries that are part of
the Surveillance, Epidemiology, and End Results
(SEER) Program of the National Cancer Institute. The
SEER Program collects data on all newly diagnosed
cancers in the states of Alaska, Connecticut, Hawaii,
Iowa, New Mexico, and Utah, as well as the metro-
politan areas of Atlanta, Detroit, Los Angeles, San
Francisco, and Seattle-Puget Sound.
Only T1 cases were included in the current study
because there were adequate numbers for the sub-
group analyses performed. Higher T-classification
levels were not included in the study in order to
minimize the probability of including cases with
undetected distant metastases.
All cases of newly diagnosed breast cancer were
selected from the 2003 edition of the SEER data tape.
These included cases diagnosed from January, 1988,
through December, 2001. Cases were excluded for a
reporting source of autopsy or death certificate only,
male gender, unknown age, subsequent breast can-
cer, in situ or histologically unconfirmed cases, size
>2 cm, tumor extension to a pathologic T4 primary,
examination of an unknown number or <10 lymph
nodes, unknown or race other than African-American
or white, unknown grade, and pathologic classifica-
tion other than N0 and N1a. After exclusions, a total
of 42,197 cases without lymph node metastases and
1724 cases with micrometastases were available for
analysis (Table 1).
Micrometastases, N1a lymph node metastases,
were defined as lymph nodes containing metastatic
foci measuring no greater than 2 mm in diameter
according to the AJCC TNM staging system.2–5 His-
tology was classified based on the ICD-O system.23
Grade was classified into three groups as ‘‘well,’’
‘‘moderate,’’ and ‘‘poor, undifferentiated, or anaplas-
tic.’’ Cases were stratified into three groups bases on
the lymph node status: N0 for no micrometastases,
N1a(1) for 1 involved lymph node, and N1a(2þ) for 2
or more involved lymph nodes.
The dependent outcome variable in this study
was ‘‘death due to breast cancer.’’ Although disease-
free survival is also an appropriate endpoint, the
SEER dataset does not maintain this as a unique
variable. It might be possible to generate this vari-
able for some cases by using the Date_of_last_con-
tact variable; however, this would not be feasible in
all cases.
Comparisons of general clinical and histologic




excluded Reason for exclusion
Remaining
count
Total number of breast cancer cases (1988–2001) 360,706
2319 Cases of male breast cancer 358,387
54,432 Cases of subsequent breast cancer 303,955
44,841 Cases of in situ cancer 259,114
3927 Cases not microscopically confirmed 255,187
108,565 Cases with tumor size greater than 2 cm 146,622
21,962 Cases with extension other than 05, 10, and 30 124,660
147 Cases of other histology 124,513
21,687 Cases of nodes coded 5–9 102,826
10,408 Cases of no nodes examined 92,418
23,645 Cases of less than 10 nodes examined 68,773
1089 Cases of unknown number of nodes examined 67,684
12 Cases of unknown status of nodes examined 67,672
8 Cases of number of positive nodes unknown 67,664
4871 Cases of unknown race or race other than
Black or White 62,793
14,939 Cases of unknown tumor grade
(other than I, II, III, or IV) 47,854
3933 Cases of pathological classification
other than N0 and N1a 43,921
SEER (Surveillance, Epidemiology, End Results) Public-Use Database (1973–2001).
Case select: breast cancer patients diagnosed from 1973–2001 in the 11 SEER registries were used for
the study. There were 360,706 breast cancer cases diagnosed from 1988–2001 in the 11 SEER regis-
tries. After exclusions there were a total of 43,921 female breast cancer patients used in the working
dataset.
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analysis. Six univariate analyses were conducted uti-
lizing the Kaplan–Meier24 survival methods with log
rank tests for the strata: lymph node status, size,
grade, histology, age, and race. A single multivariate
survival analysis was done with the Cox regression
method,25 also utilizing the same six strata. In all
survival analyses, death due to breast cancer was the
outcome of interest as the dependent variable. Cen-
soring variable for survival analyses was the Date_of_
last_contact. Right-side censoring was invoked when
lost to follow-up occurred or if the last date of con-
tact extended beyond the end of the study, meaning
the patient survived to the end of the study. All sta-
tistical analyses were conducted using the SAS v. 8
program (Cary, NC).
RESULTS
Clinical and histologic characteristics of cases are
shown in Table 2. In cases with no micrometastases,
at least 70% were the larger breast cancer size, 1.1 to
2.0 cm. This compares with at least 84% in the 2
groups [N1a(1) and N1a(2þ)] with micrometastases
and also with the larger breast cancer size. The high-
est proportion of cases, >46%, had moderately differ-
entiated (Grade 2) carcinomas. Infiltrating ductal
carcinomas (IDC) was the most common histologic
subtype, with at least 80% of the cases. More than
89% of the cases were white. Note that for most co-
variates, the 2 micrometastases groups, N1a(1) and
N1a(2þ), had similar distributions; however, both
these groups were different from the group with no
micrometastases.
The full follow-up in this study was 14 years. To
give a sense of full follow-up, 5-year and 12-year sur-
vival of N0 compared with N1a(1) and N0 compared
with N1a(2þ) cases are shown in Table 3. Log rank
tests were conducted using the full 14 years of fol-
low-up. Probability values listed in Table 3 are for
the full follow-up and not just for the 5-year or 12-
year survival. Overall, cases with either solitary and
multiple lymph node micrometastases experienced a
statistically significant decrease in 12-year survival to
88% and 89%, respectively, compared with the
decrease in lymph node-negative cases of 93%. This
represents a 5.0% and a 3.6% survival disadvantage,
respectively, compared with lymph node-negative
cases (Fig. 1). In stratified analyses, the decreased
survival associated with the presence of 1 or more
micrometastases was generally modest and variable.
The most significant survival disadvantage associated
with micrometastases was in 12-year survival of
cases with Grade 3 carcinoma. Survival of solitary
and multiple lymph node micrometastases cases
declined by 13.7% and 9.1%, respectively. This was
seen as a survival percentage of 76% and 81%,
respectively, compared with 90% for 12-year survival
in lymph node-negative cases.
TABLE 2





(2+micrometastases) N1a(1) vs. N1a(2+)
n = 41197 (n = 1,293) vs. N0 (n = 431) vs. N0 n = 1,290 vs. n = 431
% % P * % P y P {
Size, cm 1 28.3 15.6 <.001 13.2 <.001 0.228
1.1–2.0 71.7 84.4 86.8
1 22.8 19.7 15.5
Grade 2 46.3 48.8 .030 46.9 <.001 0.031
3 30.9 31.5 37.6
IDC 80.3 82.9 80.0
Histology ILC 4.2 3.8 .067 3.5 .692 0.258
Other 15.5 13.3 16.5
Age, y
<50 22.7 31.5 37.6
50–64 36.5 36.9 <.001 38.5 <.001 0.006
65 40.8 31.6 23.9
Race Black 6.6 8.6 .005 10.2 .003 0.307
White 93.4 91.4 89.8
* Chi-square analysis of N0 vs. N1a(1) for each strata (size, grade, histology, age, and race).
y Chi-square analysis of N0 vs. N1a(2þ) for each of the 5 strata.
{ Chi-square analysis of N1a(1) vs. N1a(2þ) for each of the 5 strata.
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Results of a multivariate analysis are shown in
Table 4. The hazard risk of death due to breast cancer
was 1.62 in cases with micrometastases involving 1
lymph node compared with breast cancer cases without
micrometastases. This risk increased to 1.78 in cases
with 2 or more micrometastases. White women were
only at about half the risk of death due to breast cancer
compared with African-American women. Those
women at greatest risk of dying in this study were those
who had: 1) larger initial tumor size (1.1–2.0 cm), 2) a
Grade 3 carcinoma, and 3) micrometastases.
DISCUSSION
For the past 100 years management of invasive
breast malignancies has included the performance of
an axillary lymph node dissection and histologic ex-
amination of representative sections from each
lymph node. The major limitation of this approach is
the potential to miss small metastatic foci. Despite
the limitations of routine histologic examination,
micrometastases have been noted in 8% to 10% of
lymph node-positive cases.26,27
Recognizing the potential to miss subtle meta-
static foci using standard techniques, serial sectioning
can be employed to examine a greater proportion of
the axillary lymph node volume. In series utilizing se-
rial sectioning with hematoxylin and eosin (H&E)
staining, the frequency of occult lymph node metasta-
ses was noted to increase in the range of 8% to 24%
among previously lymph node-negative cases.11,12,28
When initially negative H&E-stained, but immu-
nohistochemically positive, slides are retrospectively
examined, a number of cases with occult metastases
can be detected.29 Utilization of immunohistochemi-
cal staining has also resulted in an increase in the
TABLE 3
Kaplan-Meier Survival Associated with Micrometastases by Selected Risk Factors
N0 N1a(1) N1a(2þ)
5-Year 12-Year 5-Year 12-Year
P*
5-Year 12-Year
PySurvival Survival Survival Survival Survival Survival
LN status 0.97 0.93 0.95 0.88 <.001 0.94 0.89 <.001
Size, cm 1 0.99 0.96 0.96 0.96 .013 1.00 0.96 .765
1.1–2 0.97 0.92 0.95 0.86 .001 0.93 0.88 .002
1 0.99 0.97 1.00 1.00 .137 1.00 1.00 .459
Grade 2 0.98 0.93 0.98 0.92 .085 0.94 0.94 .028
3 0.95 0.90 0.88 0.76 <.001 0.91 0.81 .008
IDC 0.97 0.92 0.95 0.88 <.001 0.95 0.89 .015
Histology ILC 0.98 0.95 1.00 1.00 .411 1.00 1.00 .690
Other 0.98 0.94 0.97 0.80 .349 0.86 0.86 <.001
Age, y
<50 0.96 0.92 0.95 0.87 .155 0.93 0.84 .019
50–64 0.98 0.93 0.95 0.92 .001 0.93 0.93 .025
65 0.97 0.93 0.95 0.86 .006 0.95 0.92 .161
Race Black 0.94 0.88 0.94 0.87 .708 0.88 0.88 .418
White 0.97 0.93 0.95 0.89 <.001 0.94 0.89 <.001
LN, lymph node; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma.
* Separate survival curves were constructed for each of the 6 strata, risk factors, presented in Table 3.
Log rank analysis of N0 vs. N1a(1) for each strata, (LN status, size, grade, histology, age, and race).
y Log rank analysis of N0 vs. N1a(2þ) for each of the 6 strata.
TABLE 4
Multivariate Cox Analysis by Selected Risk Factors
Hazard ratio 95% CI P
LN classification N0 1.00
N1a(1) 1.62 1.26–2.10 <.001
N1a(2þ) 1.78 1.19–2.66 .005
Tumor size, cm 1.0 1.00
1.1–2.0 2.04 1.76–2.36 <.001
1 1.00
Grade 2 2.27 1.85–2.79 <.001
3 4.48 3.65–5.48 <.001
Other 1.00
Histology IDC 1.10 0.95–1.28 .207
ILC 0.60 0.41–0.88 .009
<50 1.00
Age, y 50–64 0.83 0.73–0.94 .004
65 1.05 0.93–1.18 .471
Race Black 1.00
White 0.58 0.49–0.68 <.001
CI, confidence interval; LN, lymph node.
A survival disadvantage was associated with the presence of one or multiple micrometastases in
addition to other known risk factors. Probability values based on the hazard ratio in each strata.
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frequency of occult lymph node metastases from
9% to 31% among H&E lymph node-negative
cases.17,21,30 Routine utilization of serial sectioning
and immunohistochemical staining is time-consum-
ing and expensive; therefore, it has not been practi-
cal to utilize routinely after performance of an
axillary lymph node dissection.
The current study includes cases with long-term
follow-up that predate the widespread utilization of
the sentinel lymph node biopsy technique. This
study therefore allows one to examine the long-term
impact of micrometastases detected by H&E staining.
The histologic and clinical characteristics utilized in
this study were chosen based on their known impact
on survival. In order to minimize the potential
impact of undetected lymph node metastases, cases
were excluded if fewer than 10 lymph nodes were
examined.
The shortcomings of this study are related to a
lack of a central pathologic review. Undefined histo-
logic factors of interest include the size of tumor
deposits and the location of metastatic tumor depos-
its within the lymph node.10,16 Additionally, cases
identified by immunohistochemical staining cannot
be identified, but likely involve a minimal number of
cases with long-term follow-up.
In this series, there is potential for error in deter-
mining the survival rates. The frequency of microme-
tastases is underestimated in the lymph node-negative
group, as in all studies not utilizing serial sectioning or
immunohistochemical staining. The low mortality rate
of the lymph node-negative group mitigates against a
potential Will Rogers effect, narrowing the survival
between the groups with and without micrometas-
tases. In this study, breast cancer mortality was the
main endpoint. In an audit of SEER data, the accuracy
of the data was ascertained to be 98%.31 Based on the
these assumptions, systematic errors would most
likely have a minimal impact on the conclusions of
this study.
The majority of lymph node micrometastases are
solitary.20,22 Articles by Huvos et al.1 and Fisher et al.12,26
indicate that solitary lymph node metastases do not
adversely impact survival. This opinion has been
reflected in the notation in the AJCC TNM staging
system manual that invasive breast cancers asso-
ciated with solitary lymph node micrometastases are
associated with the same survival as cases without
lymph node metastases. In contrast, Rosen14 noted
that at 12 years follow-up the survival of groups with
solitary micro- and macrometastases was nearly
identical. In the current study, solitary lymph node
micrometastases were associated with a modest 5%
(statistically significant) overall survival disadvantage
after 12 years.
In contrast, the presence of an increasing num-
ber of occult metastases was associated with a de-
crease in disease-free survival in several studies.20,22
Multiple occult metastases including cases detected
by immunohistochemistry alone have been found to
be the most significant predictor of disease-free and
overall survival.20 Consistent with these studies, the
current study found the presence of multiple micro-
metastases to be a predictor for survival. The current
study shows that the presence of 2 or more lymph
node micrometastases is associated with a modest
3.6% (statistically significant) survival disadvantage
after 12 years.
Heterogeneity in previous reported studies pre-
cludes the conclusion that micrometastases are an
independent prognostic indicator.7 The overall sur-
vival for cases with micrometastases detected by
H&E staining after an adequate axillary lymph node
dissection is modestly reduced compared with
lymph node-negative cases among T1 breast cancer
carcinomas. The adverse impact on survival of mi-
crometastases associated with Grade 3 carcinomas
indicates the highest risk of systemic disease seen
in this study. The modest survival disadvantage due
to micrometastases among the remaining subgroups
indicates that micrometastases in general are not
determinants of survival, but are a significant risk
factor.
The questions for the future include: What is the
impact of micrometastases detected by sentinel
lymph node biopsy, and is there a need for a com-
plete axillary lymph node dissection in cases with
micrometastases? Ongoing clinical trials have been
designed to address these questions. The current
study, with subgroup analyses, will provide a context
to evaluate the results of these pending clinical trials.
FIGURE 1. Kaplan--Meier survival curve.
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